Stay updated with breaking news from Phasei Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Arbele, a clinical stage biopharmaceutical company, announces the successful dosing of the first patient in Australia in Phase I Study of...
With unique STAMP mechanism of action, Scemblix could provide a new option for patients in Europe with chronic myeloid leukemia (CML) who have suffered intolerance or inadequate response with at least
Scemblix® (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif®* (bosutinib) at 96...
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial
Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif* (bosutinib) at 96 weeks (37.6% vs. 15.8%), building on 24-week